Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Posted in the last 24 hours
Fresh from the desks
Wearables Policy
A Populist Health Movement and the Insurance Industry Have Landed on the Same Device
RFK Jr.'s push for wearables and insurers' wellness programs want the same continuous body data for opposite reasons. What happens next depends on insurance rating law, not the hardware.
Clinical Trials
What a Trial of a Hundred Patients Cannot Tell You About Risk
Vykat XR looks riskier now than it did in its approval trial, and that is the expected pattern for rare-disease drugs, not proof something was missed. Here is why, and what the new data should actually change.
Drug Pricing
The $11 Insulin Pen Almost Nobody Is Buying
California's CalRx insulin launched at a fraction of the cash price and is barely selling. The reason is not that the program failed, it is that price and access are different problems.
Banking Regulation
The Home Loan Banks Get Paid First When a Member Bank Fails
The Federal Home Loan Bank System has never taken a credit loss in 94 years. That record reflects where it stands in the repayment line, not how well it underwrites, and the losses did not disappear.
Medical Billing
The Surprise-Billing Fight Now Turns on a Number One Side Gets to Calculate
A federal appeals court just handed doctors another win in the fight over the No Surprises Act's payment benchmark, the QPA. The law pulled patients out of surprise-billing disputes, but the underlying cost didn't disappear, it moved into a formula insurers calculate and providers keep suing over.
Clinical Data
What the Growing Wait for Cancer Treatment Is Really Made Of
A study of 2.7 million patients found the time from cancer diagnosis to first treatment has grown by ten days or more over a decade, consistently across six cancers. The finding is real, but it bundles two opposite things together, time that buys more precise care, and time that buys nothing but worry.
Pharma Regulation
The Hard Question Behind the Vykat Safety Warning: Was It the Drug, or the Disease?
Seven patients taking Vykat XR for Prader-Willi syndrome's relentless hunger have died, and experts are warning clinicians. None of the deaths have been definitively linked to the drug, because Prader-Willi itself carries a high baseline risk of the same cardiac and respiratory complications.
Markets
The Part of the Deficit No One Votes On Is Growing
July's record $432 billion deficit was mostly a calendar quirk, and the reversal of recent improvement was mostly a tariff-refund windfall ending. What's actually driving the deficit, compounding interest on past debt and aging-driven entitlement growth, runs on autopilot and doesn't care what any single month's headline says.
Wealth Management
Are You Really Holding Too Much Cash? It Depends Who's Asking
Wealth management calls $3 trillion in idle cash "a problem." But that framing describes lost fee revenue for the industry as much as it describes a mistake by investors, and cash paying 4% today is a very different decision than cash paying nothing was a few years ago.
B2B Research
Most Popular Research Articles
Intent Data
Intent Data Providers For B2B
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
Knowledge Management
Knowledge Management Solutions
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
MDR
Managed Detection And Response Services
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
MDR Europe
Managed Detection And Response Services In Europe
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Manufacturing Tech
Manufacturing Technology Services
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Market Intelligence
Market And Competitive Intelligence Platforms
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Open Banking
Open Banking Intermediaries
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Change Management
Organizational Change Management Services
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
PLM
Product Lifecycle Management Platforms For Discrete Manufacturers
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Announcements
News from Mavengity
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareResearch
Gartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse Research
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.